復興亞洲(00274.HK)擬折讓約39.1%配發合共8億股
格隆匯1月30日丨復興亞洲(00274.HK)發佈公吿,於2024年1月30日,公司與認購方訂立認購協議,據此,公司已有條件同意配發及發行合共8億股股份。認購股份佔(i)公司於本公吿日期已發行股本的約37.9%;及(ii)公司經認購股份擴大的已發行股本的約27.5%。認購價每股認購股份0.028港元,較1月30日收市價每股0.046港元折讓約39.1%。
認購事項所得款項總額預期將約為22.4百萬港元,而認購事項所得款項淨額將約為22.2百萬港元。所得款項擬用於結算專業費用、償還未償還貸款、金礦營運所需的營運資金。
董事認為,認購事項可降低集團的資產負債比率及改善集團的財務狀況。因此,董事認為認購事項屬公平合理,且符合公司及其股東整體的最佳利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.